Bio-Rad offers a portfolio of recombinant, monoclonal anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays
Scientists have identified the binding pocket for molecules that can stabilize a key braking mechanism in cancer—opening the door to the development of drugs that target it